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Introduction: Although previous studies found that cigarette smoking is associated with risk of rheumatoid arthritis
(RA), the dose-response relationship remains unclear. This meta-analysis quantitatively summarizes accumulated
evidence regarding the association of lifelong exposure to cigarette smoking assessed as pack-years with the risk
of RA.
Methods: Relevant studies were identified by a search of MEDLINE and EMBASE from 1966 to October 2013, with
no restrictions. Reference lists from retrieved articles were also reviewed. Studies that reported relative risks (RR) or
odds ratio (OR) estimates with 95% confidence intervals (CIs) for the association between pack-years of cigarette
smoking and rheumatoid arthritis were included in a dose-response random-effects meta-regression analysis.
Results: We included 3 prospective cohorts and 7 case-control studies in the meta-analysis. They included a total
of 4,552 RA cases. There was no indication of heterogeneity (Pheterogeneity = 0.32) and publication bias did not affect
the results. Compared to never smokers, the risk of developing RA increased by 26% (RR = 1.26, 95% CI 1.14 to 1.39)
among those who smoked 1 to 10 pack-years and doubled among those with more than 20 pack-years (RR for 21
to 30 pack years = 1.94, 95% CI 1.65 to 2.27). The risk of RA was not increasing further for higher exposure levels (RR
for >40 pack-years = 2.07, 95% CI 1.15 to 3.73). The risk of RA was statistically significantly higher among rheumatoid
factor (RF)-positive RA cases (RR = 2.47, 95% CI 2.02 to 3.02) compared to RF-negative (RR = 1.58, 95% CI 1.15 to
2.18) when comparing the highest versus lowest category of pack-years for the individual studies.
Conclusions: Lifelong cigarette smoking was positively associated with the risk of RA even among smokers with a
low lifelong exposure. The risk of RA did not further increase with an exposure higher than 20 pack-years.Introduction
Cigarette smoking is considered an established risk
factor for the development of rheumatoid arthritis (RA),
an autoimmune inflammatory disease. This was confirmed
by a published meta-analysis on smoking and risk of
RA that showed a 40% higher risk among ever smokers
compared to never smokers [1]. However, little is known
regarding the dose-response relationship between quantity
of cigarette smoking and increase in the risk of RA. Previ-
ous epidemiological studies showed an increasing RA risk
associated with increasing cigarette smoking [2-4], while a
recently published study reported that even light smoking
was associated with an increased risk of RA [5]. Light
smoking as well as heavy smoking could increase the risk* Correspondence: Alicja.Wolk@ki.se
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distribution, and reproduction in any mediumof RA due to the triggering of the immune system against
citrullinated proteins antigens [6].
The aim of the present study was to quantitatively
summarize the accumulated evidence on the relation
between lifelong exposure to cigarette smoking and
risk of developing rheumatoid arthritis by performing
a dose-response meta-analysis. As a measure of life-
long exposure we used pack-years of smoking.Methods
We searched MEDLINE and EMBASE databases for
relevant studies published from 1966 through October
2013 using the search terms “rheumatoid arthritis” or “RA”
combined with “smoke”, “smoking”, “cigarette smoking”
or “pack-years”, with no restrictions. Studies were excluded
if they did not meet the selection criteria: use of an observa-
tional design (cohort or case-control design), examination
of smoking as the main exposure and RA as the mainntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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for categories of pack-years (obtained by multiplying the
number of cigarettes smoked per day by the number of
years the person has smoked, divided by 20). In case of
multiple publications from the same study, we selected
the publication with estimates on the entire study cohort
[2,4], instead of the publications focusing only on in-
teractions [7] or anticitrullinated protein antibody (ACPA)
positive RA cases [8].
From each study we extracted information regarding
publication data (first author’s last name, year of publication
and country of the studied population), number of RA
cases, cohort size or number of controls, follow-up period
for cohorts and study period for case-control studies,
exposure specific relative risk or odds ratio estimates with
their corresponding 95% confidence intervals (CIs), and
variables controlled for in the multivariable model (Table 1).
From each study, we extracted the relative risk or odds ratio
estimates from the maximally adjusted model to reduce
the risk of possible unmeasured confounding. Data were
extracted independently by two researchers (DDG and NO).
The study quality was assessed using the Newcastle-
Ottawa Quality Assessment Scale (NOQAS) for cohort
and case-control studies, with which each study was judged
based on the selection of the study groups, the comparabil-
ity of the groups, and the ascertainment of exposure and
outcome [9]. The score ranged between 0 (as poor) and 9
(as excellent). The present work follows the recommenda-
tions of the PRISMA Statement [10].
Statistical analysis
We conducted a two-stage dose-response random-effects
meta-regression analysis [11,12], and we estimated the
dose-response relationship curve by taking into account
the covariance among risk estimates for different exposure
categories [12]. The possible non-linear relationship be-
tween pack-years of smoking and risk of RA was modeled
using restricted cubic splines (with three knots). This
method requires stating the distribution of cases and non-
cases or person-time and the relative risk (RR) or the odds
ratio (OR) with its confidence intervals for at least three
quantitative exposure categories. For this reason, a study
that reported only two exposure categories was excluded
from this meta-analysis [13]. For another study that did
not provide the distribution of cases and non-cases for
each exposure level [14], we used the method proposed by
Hamling et al. [15] to calculate the pseudo-counts to be
able to estimate the covariance of the published ORs. For
a study that reported only results stratified by menopausal
status [16], we combined the two stratum-specific ORs
using inverse variance weighted averages [17]. The mid-
point of each exposure category was assigned to each
corresponding risk estimate. We assigned the midpoint of
the upper open-ended category assuming that they hadthe same amplitude as the preceding categories, except for
one study [5], which reported the median value of the
highest category. We assigned a null value to the lowest
category, composed in all the studies by never smokers.
By testing if the second parameter of the restricted cubic
spline model was equal to 0, we observed a limited evi-
dence of a non-linear relationship between pack-years of
smoking and RA (P = 0.078). However, the restricted cubic
spline model resulted in the best fitting model in terms of
the Akaike Information Criterion (AIC) when comparing it
against a linear model (AICsplines = -70.0; AIClinear = -57.4).
We additionally performed a random-effects meta-
analysis comparing the highest versus the lowest category of
pack-years within each specific study. For this analysis the
approach developed by DerSimonian and Laird was used
[17]. We conducted a sensitivity analysis in which one study
at a time was removed in order to evaluate the influence of
each study on the overall estimate. We also performed ana-
lyses stratified by study design (cohort, case-control), gender
and rheumatoid factor (RF) type (positive, negative).
In all meta-regression models, statistical heterogeneity
between studies was evaluated with the Cochran’s Q-test
and the I2 statistic [18], which assess the proportion of total
variation due to between-study variation. Publication bias
was investigated by Egger’s regression asymmetry test [19].
All reported P-values are two-sided. All statistical analyses
were carried out with Stata, version 12.1 (StataCorp,
College Station, TX).
Results
Of the 29 studies that reported an estimate of the associ-
ation between cigarette smoking and rheumatoid arthritis,
only 3 cohort studies [4,5,20] and 7 case-control studies
[2,14,16,21-24] evaluated the dose-response relationship
between pack-years and RA, and were included in this
meta-analysis (Figure 1). Of the 10 studies that met the
predefined inclusion criteria, 4 were from North America
[4,14,16,20], 5 from Europe [2,5,21,22,24], and 1 from
Malaysia [23], and they included a total of 181 100 subjects
and 4,552 RA cases (Table 1). The median of the highest
category of number of pack-years analyzed in each study
ranged between 15 and more than 55 pack-years, while the
reference group for all studies was never smokers. Four
studies provided risk estimates for women only [4,5,16,20]
and two studies provided risk estimates for men and
women separately [21,22]. Using the NOQAS quality as-
sessment, all 10 studies were assessed to have moderate
quality (Table 1). All studies included in this meta-analysis
showed a significant dose-response increased risk, except
one [21], which reported a non-significant positive associ-
ation between RA and cigarette smoking among women.
In a dose-response analysis, we modeled the relation-
ship between pack-years of cigarette smoking and RA risk
using a restricted cubic splines model. The non-linear
Table 1 Characteristics of studies on rheumatoid arthritis and pack-years












Criswell et al., 2002 [20] Iowa Women’s Health Study,
USA, 1986 to 1997
Women 158/31,336 0 to 50a ≥40 Total 1.7 (1.0 to 3.0) Age, body mass index, alcohol use,
coffee consumption, marital status,
occupation, age at menopause, use
of oral contraceptives and hormone
replacement therapy.
8
Costenbader et al., 2006 [4] Nurses’ Health Study, USA,
1976 to 2002
Women 680/103,818 0 to 45a >40 Total 1.86 (1.46 to 2.38) RF +* 2.22
(1.63 to 3.02) RF-* 1.43 (0.96 to 2.12)
Age, body mass index, alcohol intake,
father’s occupation, age at menarche,




Di Giuseppe et al., 2013 [5] Swedish mammography
cohort, 2003 to 2010
Women 219/34,101 0 to 28b >22 Total 1.82 (1.19 to 2.79) Age, menopause status, parity, alcohol




Voigt et al., 1994 [16] Population-based controls,
USA, 1986 to 1991
Women 349/1,457 0-27a >20 Total 1.49 (1.06 to 2.10) Age, body mass index. 7
Hutchinson et al., 2001 [24] Hospital-based controls, UK Men +Women
239/239
0 to 55a >50 Total 8.41 (2.45 to 28.84) Matched for age, gender and social
class.
7
Olsson et al., 2001 [21] Population-based controls,
Sweden, 1980 to 1995
Men 91/203
Women 154/222
0 to 27a ≥20 Total men 2.7 (1.2 to 5.8) Total
Women 1.8 (0.7 to 4.6) RF + Men
3.4 (1.5 to 8.4) RF +Women 2.5
(0.9 to 6.7)
Age, economic status. 7
Stolt et al., 2003 [2] Population-based controls,
Sweden, 1996 to 2000
Men +Women
486/724
0 to 25a ≥20 RF + 2.7 (1.8 to 3..9) Age, residential area and gender. 7
Pedersen et al., 2006 [22] Population-based controls,
Denmark, 1988 to 2003
Men 149/291 Women
366/478
0 to 25a >20 Total men 2.00 (1.12 to 3.58) Total
Women 2.07 (1.35 to 3.16)
Birth year, year of RA diagnosis, gender. 7




0 to 15a ≥10 Total 2.37 (1.56 to 3.60) RF + 2.51
(1.63 to 3.87) RF- 1.93 (1.11 to 3.35)
Age, gender. 7
Yahya et al., 2012 [23] Population-based controls,
Malaysia, 2005 to 2009
Men +Women
1056/1416
0 to 25a ≥20 Total 2.3 (1.0 to 5.5) Matched for age, gender and residential
area. Additionally adjusted for formal
education and ethnicity.
6
aMidpoint in the lowest-highest category bMedian of the highest category.
§The lowest category corresponded to never smokers in all study except the study of Navarro-Compàn et al., that used <20 pack/years as reference level.

















3,561 records identified through database searching: 
1,143 records identified in PubMed
2,418 records identified in EMBASE
756 records excluded for duplication
2,776 records excluded as they did not 
reported information on the 
association between cigarette 
smoking and RA
29 potentially relevant articles identified for full text review 
19 articles excluded:
16 had no data on pack-years
2 were overlapping cohort studies 
1 has the exposure only as   
dichotomous variable
Included in the meta-analysis:
3 cohort studies
7 case-control studies 
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Cigarette smoking, pack-years
Linear Model
Restricted Cubic Splines Model
95% Confidence Intervals
Figure 2 Non-linear dose-response relationship between
pack-years of cigarettes smoking and relative risk of RA. Relative
risk (solid line) and 95% confidence interval (long dashed lines)
from the restricted cubic splines model. The short dashed line
represents the RR from the linear model. Estimates reported in the
table are based on median value of each category.
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significant increased risk of developing RA with increasing
number of pack-years smoked up to 20 pack-years, and
then the relative risk stabilized approximately at the value
of 2. The risk of RA was 26% higher (RR = 1.26, 95% CI
1.14 to 1.39) for those who smoked 1 to 10 pack-years
of cigarette (median value 5.5) compared to never smokers,
while the risk was two-fold for those smoking 21 to 30
pack-years (RR = 1.94, 95% CI 1.65 to 2.27) and was similar
even for higher levels of cigarette smoking (RR for >40
pack-years = 2.07, 95% CI 1.15 to 3.73) (Table 2).
The comparison of the highest vs. the lowest categories
of pack-years of smoking from the individual studies wasTable 2 Relative risks (RRs) and 95% confidence intervals
(95% CIs) for categories of pack-years of smoking
Pack-years RR (95% CI)
Never smokers 1.00
1 to 10 1.26 (1.14 to 1.39)
11 to 20 1.70 (1.44 to 2.01)
21 to 30 1.94 (1.65 to 2.27)
31 to 40 2.02 (1.44 to 2.82)
>40 2.07 (1.15 to 3.73)
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showing a two-fold increase of RA risk (overall RR = 2.02,
95% CI 1.75 to 2.33). A sensitivity analysis excluding one
study at a time showed that the overall RRs ranged be-
tween 1.92 and 2.10. Q test for heterogeneity of the results
between specific studies was not statistically significant
(Q = 12.61, Pheterogeneity = 0.32). There was no evidence of
publication bias (P-value from the Egger’s regression
asymmetry test was 0.10).
We conducted stratified analyses by study design, gender
and rheumatoid factor type. The RR comparing the highest
vs. the lowest category of pack-years of smoking was 1.83
(95% CI 1.50 to 2.23; Q = 0.09, Pheterogeneity = 0.96) among
cohort studies and 2.19 (95% CI 1.76 to 2.72; Q = 11.22,
Pheterogeneity = 0.19) among case-control studies (Figure 3).
The RR estimate was 1.78 (95% CI 1.52 to 2.08; Q = 1.69,
Pheterogeneity = 0.89) among women and 2.22 (95% CI 1.39
to 3.55; Q = 0.36, Pheterogeneity = 0.55) among men. Four
studies reported estimates for RF-positive RA [2,4,14,21]
and only two for RF-negative RA [4,14]. Among RF-
positive cases the RR comparing the highest vs. the lowest
category of pack-years of smoking was 2.47 (95% CI 2.02
to 3.02; Pheterogeneity = 0.88), while it was 1.58 (95% CI 1.15
to 2.18, Pheterogeneity = 0.39) among RF-negative cases. These
estimates were statistically significantly different (P-value
0.022).
Discussion
The findings from this dose-response meta-analysis showed
some evidence of a non-linear association between lifelong
cigarette smoking and RA. The association was statisticallyFigure 3 Forest plot of relative risk estimates for rheumatoid arthritis
lowest category). CI indicates confidence intervals; RR indicates relative ris
variance). *Test for heterogeneity: cohort studies, P = 0.96, I2 = 0.0%; case-cosignificant even among those smoking less than 10 pack-
years. For more than 20 pack-years the risk of RA was
two-fold compared to never smokers and it stabilized with
no further increase for higher levels. The risk among
RF-positive RA cases was statistically significantly higher
than the risk among those RF-negative.
The dose-response meta-analysis was based on a limited
number of studies. Only 10 studies satisfied the inclusion
criteria, of which only 3 were prospective cohort studies.
In the analyses we did not observe evidence of heterogen-
eity. Publication bias did not affect the findings of this
meta-analysis. Results from this meta-analysis are in line
with the results from the previous meta-analysis [1],
showing an increased RA risk associated with cigarette
smoking. However, this meta-analysis of the dose-response
relationship between cigarette smoking and RA can allow a
better understanding of the association.
Among the limitations of the present study, we have
to consider the limited number of studies addressing the
dose-response association between lifelong exposure to
cigarette smoking and RA. Moreover, a meta-analysis is
influenced by the quality of the summarized studies. The
quality scale used in this manuscript indicates a moderate
quality for all the studies. However, this quality scale does
not take into account the differences between case-control
and prospective cohort design, such as different biases (for
example, case-control studies may be affected by recall
bias, while prospective cohort are not). Moreover, the
pooled estimate from this meta-analysis could have been
affected by a potential residual confounding from each
study. In particular, the numbers of confounders takenrisk associated with pack-years of cigarette smoking (highest vs.
k. The size of each square is proportional to the study’s weight (inverse
ntrol studies, P = 0.19, I2 = 28.7%, overall studies, P = 0.32, I2 = 12.7%.
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meta-analysis were in general limited. This could explain
the difference between the pooled OR from case-control
studies and the pooled RR from prospective cohort studies.
Moreover, this difference could also be explained by the
different study populations: prospective cohort studies
analyzed only women while all case-control studies except
one [16] included both men and women.
The biological effect of smoking in the development
of rheumatoid arthritis is still unclear. However, it is
known that certain cigarette smoke components, such
as nicotine, hydrocarbons and carbon monoxide, may
enhance immune reactions, and it has been found that
in certain inbred strains of rodents these components
cause arthritis without contributions from other agents
[25-27]. Moreover, it has been hypothesized that smok-
ing interacts with HLA-DR SE genes in triggering and
persuading immunity against citrullinated proteins, and
that this immunity is specific for RA [6,28]. The ob-
served non-linear shape of the dose-response associ-
ation in this meta-analysis is compatible with this
triggering mechanism. RF-positive RA is more likely to
be associated with the HLA-DR4 shared epitope [29]
than RF-negative RA. This can explain the difference in
risk between RF-positive and RF-negative RA cases ob-
served in the meta-analysis.
Conclusion
Our study showed some evidence of a non-linear dose-
response relationship between lifelong smoking and risk
of RA. The risk increased at a relatively low level of lifelong
exposure to smoking (≤10 pack/years) and stabilized
to approximately a double risk for a smoking exposure
higher than 20 pack-years.
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